Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 15.13

Immunosuppression Use for Maintenance by Regimen

Two Years Following Transplantation, 1999 to 2007

Recipients with Heart Transplants

  Transplant Year
1999 2000 2001 2002 2003 2004 2005 2006 2007
Transplants 2,188 2,199 2,202 2,155 2,057 2,015 2,125 2,193 2,209
Functioning Graft at 2 Years PostTx 1,670 1,729 1,748 1,715 1,658 1,645 1,718 1,783 1,819
With Maintenance Use Recorded at 2 Years PostTx 1,605 1,706 1,704 1,661 1,648 1,624 1,541 1,528 1,582
CyA 2.1% 1.8% 1.2% 1.0% 1.0% 0.7% 0.1% 0.5% 0.5%
Tac 1.8% 2.1% 2.0% 2.0% 1.6% 2.8% 3.2% 3.7% 4.2%
--- + MMF/MPA 0.1% 0.1% 0.2% 0.2% 0.3% 0.2% 0.0% 0.3% 0.1%
CyA + MMF/MPA 12.3% 14.1% 12.9% 11.4% 12.0% 10.8% 10.6% 9.9% 9.0%
Tac + MMF/MPA 5.2% 7.2% 12.2% 11.2% 15.8% 18.9% 21.9% 24.0% 28.0%
--- + OtherAntimet 0.1% 0.1% 0.1% 0.0% 0.0% 0.1% 0.0% 0.0% 0.1%
CyA + OtherAntimet 3.9% 3.2% 2.1% 2.0% 1.3% 1.6% 1.1% 1.4% 0.8%
Tac + OtherAntimet 1.7% 1.1% 1.5% 1.6% 1.5% 1.4% 2.1% 1.8% 2.6%
--- + MMF/MPA + OtherAntimet 0.0% 0.0% 0.1% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0%
CyA + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1% 0.1% 0.0%
--- + Siro/Evero 0.1% 0.0% 0.1% 0.0% 0.1% 0.0% 0.0% 0.1% 0.1%
CyA + Siro/Evero 0.2% 0.6% 0.4% 1.7% 1.5% 0.9% 0.5% 1.2% 1.2%
Tac + Siro/Evero 0.2% 0.4% 1.2% 2.7% 2.5% 2.2% 2.5% 2.1% 2.3%
--- + MMF/MPA + Siro/Evero 0.0% 0.1% 0.2% 0.3% 0.4% 0.7% 1.6% 1.4% 1.3%
CyA + MMF/MPA + Siro/Evero 0.1% 0.1% 0.4% 0.4% 0.4% 0.3% 0.3% 0.3% 0.0%
Tac + MMF/MPA + Siro/Evero 0.0% 0.2% 0.1% 0.3% 0.4% 0.7% 0.5% 0.7% 0.8%
--- + OtherAntimet + Siro/Evero 0.0% 0.1% 0.1% 0.1% 0.1% 0.2% 0.1% 0.2% 0.1%
CyA + OtherAntimet + Siro/Evero 0.1% 0.1% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.2% 0.0% 0.0% 0.0% 0.1% 0.0%
--- + Steroids 0.5% 0.1% 0.4% 0.3% 0.2% 0.2% 0.1% 0.1% 0.0%
CyA + Steroids 5.4% 2.1% 1.7% 1.4% 1.4% 0.8% 1.0% 0.7% 1.2%
Tac + Steroids 2.8% 2.8% 3.4% 3.0% 3.4% 3.3% 3.3% 2.5% 2.8%
--- + MMF/MPA + Steroids 0.2% 0.2% 0.9% 0.5% 0.2% 0.2% 0.3% 0.1% 0.1%
CyA + MMF/MPA + Steroids 29.9% 30.9% 25.9% 20.8% 18.9% 15.8% 15.0% 13.6% 11.5%
Tac + MMF/MPA + Steroids 14.5% 17.6% 20.0% 20.5% 21.4% 23.6% 24.5% 24.3% 23.8%
--- + OtherAntimet + Steroids 0.1% 0.1% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet + Steroids 9.0% 5.7% 3.0% 2.9% 1.3% 1.7% 0.6% 0.7% 0.3%
Tac + OtherAntimet + Steroids 2.8% 2.8% 1.8% 2.0% 2.0% 1.6% 1.4% 1.8% 2.2%
--- + Siro/Evero + Steroids 0.2% 0.3% 0.5% 0.6% 0.7% 0.3% 0.3% 0.4% 0.1%
CyA + Siro/Evero + Steroids 1.1% 1.3% 0.8% 1.3% 2.1% 1.2% 1.0% 1.9% 2.1%
Tac + Siro/Evero + Steroids 1.0% 2.1% 3.4% 4.5% 4.1% 2.2% 2.5% 2.0% 1.3%
Other Regimen 4.7% 3.1% 3.4% 6.7% 5.6% 7.5% 5.4% 4.1% 3.6%


Source: OPTN/SRTR Data as of October 1, 2010.

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.